Clearmind Medicine Praises FDA Priority Review Order and MEAI’s Inclusion in VA Trial Bill
Clearmind Medicine welcomed President Trump's April 18 Executive Order directing the FDA to prioritize breakthrough-designated psychedelic therapies and expand access, boosting regulatory momentum for its non-hallucinogenic neuroplastogen pipeline. Its proprietary MEAI was named in H.R.7091 for VA-supported trials and is in Phase I/IIa studies at Yale and Johns Hopkins.
1. Executive Order Spurs Regulatory Momentum
On April 18, President Trump signed an Executive Order Accelerating Medical Treatments for Serious Mental Illness, directing the FDA to fast-track breakthrough-designated psychedelic therapies and expand patient access pathways. Clearmind’s non-hallucinogenic neuroplastogen candidates stand to benefit from prioritized review processes, potentially shortening timelines to market.
2. MEAI Named in Bipartisan VA Access Bill
Clearmind’s proprietary compound MEAI was explicitly referenced in H.R. 7091 – Expanding Veterans’ Access to Emerging Treatments Act, which, if enacted, would authorize VA-supported clinical trials and expanded access protocols targeting alcohol use disorder and related conditions among veterans.
3. Phase I/IIa Trials Underway at Leading Institutions
The company is advancing FDA-approved Phase I/IIa clinical studies of lead candidate CMND-100 (MEAI) for alcohol use disorder at Yale School of Medicine and Johns Hopkins University, aiming to demonstrate safety, tolerability and preliminary efficacy in treatment-resistant populations.